Welcome to Eventide’s site for Institutional Investors
Login to access resources for institutional investors. By submitting this form, you affirm that you are an institutional investor, and you agree to Eventide’s Online Privacy Policy.
Eventide’s story was born from a desire to honor God and serve others in how we invest. We anchored our investment philosophy in a biblical worldview, and asked the question, “How do we love our neighbors through the way we invest?”
Eventide’s story was born from a desire to honor God and serve others in how we invest. We anchored our investment philosophy in a biblical worldview, and asked the question, “How do we love our neighbors through the way we invest?”
Eventide’s story was born from a desire to honor God and serve others in how we invest. We anchored our investment philosophy in a biblical worldview, and asked the question, “How do we love our neighbors through the way we invest?”
Eventide’s story was born from a desire to honor God and serve others in how we invest. We anchored our investment philosophy in a biblical worldview, and asked the question, “How do we love our neighbors through the way we invest?”
Eventide’s story was born from a desire to honor God and serve others in how we invest. We anchored our investment philosophy in a biblical worldview, and asked the question, “How do we love our neighbors through the way we invest?”
Eventide’s story was born from a desire to honor God and serve others in how we invest. We anchored our investment philosophy in a biblical worldview, and asked the question, “How do we love our neighbors through the way we invest?”
Co-Chief Investment Officer, Senior Portfolio Manager, Managing Director, Founding Member
Finny Kuruvilla, MD, PhD, serves as a Co-Chief Investment Officer, Senior Portfolio Manager for Eventide’s strategic growth strategies and healthcare & life sciences strategies, a Managing Director for Eventide Ventures, as well as Founding Member of Eventide.
Dr. Kuruvilla has a background in healthcare, statistics, and investing. Concurrent with his early years at Eventide, he was a Principal at Clarus Ventures, a healthcare and life sciences venture capital firm subsequently acquired by Blackstone. Earlier in his career, Dr. Kuruvilla was a postdoctoral research fellow at the Broad Institute of Harvard and MIT, where he led the development of a new microarray between the Broad Institute and a publicly-traded company Affymetrix. Prior to his investing career, Dr. Kuruvilla was resident, chief resident, and fellow at the Brigham and Women’s Hospital and Boston Children’s Hospital.
Dr. Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a SM in Electrical Engineering and Computer Science from MIT, and a BS in Chemistry from Caltech.
